PHK
CUE icon

Point72 Hong Kong’s Cue Biopharma CUE Stock Holding History

Point72 Hong Kong’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed -$1K – 2007
2022
Q2 		$1K Sell
8
-72
-90% -$8.42K ﹤0.01% 1809
2022
Q1 		$12K Buy
+80
New +$17K ﹤0.01% 1580
2021
Q1 		– Sell
-1
Closed -$1K – 1873
2020
Q4 		$1K Buy
+1
New +$400 ﹤0.01% 1657
2020
Q3 		– Hold
0
– – – 1255
2020
Q2 		– Hold
0
– – – 1179

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Hong Kong's CUE Position: Q3 2022 in Review

Point72 Hong Kong sold out of Cue Biopharma (CUE) in Q3 2022, closing a stake of 8 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in CUE in Q4 2020 and held it in 3 quarters. The position peaked at $12K in Q1 2022. 64 funds tracked by Wall St. Rank hold CUE as of Q3 2022.

  • Point72 Hong Kong reported no remaining Cue Biopharma position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 8 Cue Biopharma shares in Q3 2022, an estimated $1K.
  • Point72 Hong Kong first reported a position in Cue Biopharma in Q4 2020 and held it in 3 quarters.
  • Point72 Hong Kong's Cue Biopharma position peaked at $12K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.